Nebilet Hct (Hydrochlorothiazide, Nebivolol)

Nebilet HCT is used as an antihypertensive agent that lowers blood pressure through combined beta‑blockade and diuretic action.

• Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output and plasma volume.
• Essential hypertension: improves long‑term blood pressure control when monotherapy is insufficient.
• Isolated systolic hypertension: helps achieve target systolic values in older adults.

• Nebivolol selectively blocks β1‑adrenergic receptors, diminishing heart rate and contractility, while also stimulating endothelial nitric‑oxide release for vasodilation. Hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water, thereby lowering plasma volume and peripheral resistance.

Nebilet HCT may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances such as low potassium
• Cold extremities

Serious or Rare Side Effects

• Severe hypotension
• Acute gout attacks
• Pancreatitis
• Allergic reactions including rash or angioedema
• Significant electrolyte imbalance (e.g., hyponatremia, hypokalemia)

Before initiating Nebilet HCT, clinicians should evaluate patient history and monitor relevant parameters.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Renal function: assess creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Electrolytes: check serum potassium and sodium levels regularly.
• Diabetes: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms.
• Discontinuation: avoid abrupt cessation; taper under medical supervision.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Nebilet HCT can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive hypotension.
• NSAIDs: may blunt diuretic efficacy and raise blood pressure.
• Potassium‑sparing diuretics or supplements: increase risk of hyperkalaemia.
• Strong CYP2D6 inhibitors (e.g., fluoxetine): raise nebivolol plasma levels.
• Lithium: thiazide component can raise lithium concentrations.

Moderate Interactions (Monitor Closely)

• Digoxin: monitor serum levels due to possible electrolyte changes.
• Antidiabetic agents: enhanced hypoglycaemia risk; adjust glucose monitoring.
• Alcohol: may exacerbate dizziness and hypotension.
• Anticholinergic drugs: may increase risk of urinary retention.
• Corticosteroids: may counteract diuretic effect, requiring dose adjustments.